How Jan Skvarka and Trillium went from down and out to buyout with Pfizer
How do you pull off one of the most lucrative biotech turnarounds in history?
You begin, it seems, by calling up the chief business officer of a Big Pharma sitting beneath a $30 billion-plus windfall and asking if he might want to get in on a modest investment in an up-and-coming company.
At least that’s what Trillium CEO Jan Skvarka asked Pfizer global business vice president John DeYoung in early summer 2021. Trillium was valued at a couple of shades under $1 billion at the time, an astronomical valuation from the penny stock mire it sat at when Skvarka arrived in October 2019.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.